Preferred Label : MAGE-A3-specific Immunotherapeutic GSK 2132231A;
NCIt synonyms : Antigen Specific Cancer Immunotherapeutic GSK 2132231A; ASCI GSK 2132231A; MAGE-A3 ASCI GSK 2132231A;
NCIt definition : An immunotherapeutic agent composed of a fusion protein containing the human melanoma-associated
antigen MAGE-A3 fused to a lipidated protein D derived from Haemophilus influenzae
and combined with the immunoadjuvant AS15, with potential immunostimulating and antineoplastic
activities. Upon intramuscular (IM) administration, GSK 2132231A may stimulate a specific
cytotoxic T-lymphocyte (CTL) response against MAGE-A3-expressing tumor cells, resulting
in tumor cell death. MAGE-A3, a tumor-associated antigen, is upregulated in a variety
of cancer cell types. This fusion protein may boost antitumoral immune responses.
AS15, a liposomal formulation containing the immunostimulating compounds CpG 7909,
3-O-desacyl-4'-monophosphoryl lipid A (MPL), and QS-21, increases the immune response
against MAGE-A3-expressing tumors.;
Molecule name : GSK2132231A; GSK 2132231A;
Origin ID : C123649;
UMLS CUI : C4053638;
Semantic type(s)
- concept_is_in_subset
- has_target
